Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of methyl flavonoid compound in preparation of medicine for preventing or treating acute lung injury and/or acute respiratory distress syndrome

A technology for acute respiratory distress and acute lung injury, applied in the field of medicine, can solve problems such as inhibiting pulmonary edema, achieve the effects of inhibiting pulmonary edema, delaying or weakening respiratory distress, and reducing lung wet weight

Pending Publication Date: 2022-05-06
CATCH BIO SCI & TECH
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Therefore, the technical problem to be solved in the present invention is to overcome the defects that the medicines for the treatment of acute lung injury (acutelung injury, ALI) / acute respiratory distress syndrome (ARDS) in the prior art cannot inhibit pulmonary edema while anti-inflammation, Thereby providing a kind of application of methyl flavonoid compound in the preparation of prevention or treatment of acute lung injury and / or acute respiratory distress syndrome medicine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of methyl flavonoid compound in preparation of medicine for preventing or treating acute lung injury and/or acute respiratory distress syndrome
  • Application of methyl flavonoid compound in preparation of medicine for preventing or treating acute lung injury and/or acute respiratory distress syndrome
  • Application of methyl flavonoid compound in preparation of medicine for preventing or treating acute lung injury and/or acute respiratory distress syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] This example provides a preparation method for compounds 1-1 to 1-12, the specific structure of which is shown in the table below:

[0058] The structure of compound 1-1~1-12 in table 1

[0059]

[0060] Specifically include the following steps:

[0061] Take 20kg of commercially available false eagle's claw roots, crush them, add 120L of ethanol with a volume fraction of 85%, and then extract at 70°C for 3 times, each time for 1 hour, collect and combine the filtrates, and concentrate to obtain an extract. Suspend the extract with water at 60°C to a volume of 5L, and after cooling, extract with petroleum ether, chloroform, ethyl acetate, and n-butanol in sequence. Each solvent is extracted 3 times, and the amount of each solvent is 5L, and the petroleum ether extract is collected. Fr.A, chloroform extract Fr.B.

[0062] Concentrate the petroleum ether extract Fr.A under reduced pressure to remove petroleum ether, then use a silica gel column (column diameter 6cm×h...

Embodiment 2

[0071] This example provides a preparation method of compounds 2-1 to 2-16, the specific structures of which are shown in the table below.

[0072] The concrete structure of table 2 compound 2-1~2-16

[0073]

[0074] It specifically includes the following steps: Weigh 20 kg of dried Spanish clover (Desmodium incanum) whole plant, chop it up, add 6 times the amount of methanol with a volume fraction of 85%, soak and extract at room temperature for 2 times, each time for 24 hours, combine the filtrates, and concentrate to no alcohol smell (solid content 1.45kg), add water to suspend to 5L, extract with cyclohexane, dichloromethane, ethyl acetate, n-butanol successively, each solvent extracts 2 times, each solvent consumption is 5L, collect dichloromethane The extract was concentrated to obtain Fr.A, and the ethyl acetate extract was collected and concentrated to obtain Fr.B.

[0075] Fr.A was separated by a silica gel column (column diameter 6cm×height 60cm, column volume 1...

Embodiment 3

[0084] This example provides a preparation method for compounds 3-1 to 3-32, the specific structures of which are shown in the table below.

[0085] The concrete structure of table 3 compound 3-1~3-32

[0086]

[0087] Concretely include the following steps: take 30 kg of dry root of cultivated Mirabilis jasmine from Tibet in the market, crush it and extract it 3 times with 180 L volume fraction of 75% methanol at 70° C. for 2 hours each time, collect and combine the filtrates, and concentrate to obtain extract (solid content 1.68kg). Suspend the extract with water at 60°C to 5L, and after cooling, extract with petroleum ether, ethyl acetate, and n-butanol in sequence. Each solvent is extracted twice, and the amount of each solvent is 5L. Collect petroleum ether extracts Fr.A, Ethyl acetate extract Fr.B.

[0088]After concentrating Fr.A under reduced pressure to remove the solvent, it was separated on a silica gel column (column diameter 6cm×height 60cm, column volume 1.5...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicines, in particular to application of a methyl flavonoid compound in preparation of a medicine for preventing or treating acute lung injury and / or acute respiratory distress syndrome. The methyl flavonoid compound provided by the invention has a structure as shown in the following formula: the methyl flavonoid compound can obviously inhibit inflammatory response, inhibit release of inflammatory factors IL-1beta, IL-6, TNF-alpha and MPO, reduce the content of inflammatory factors in alveolar lavage fluid and serum of mice with acute lung injury, and also can obviously inhibit pulmonary edema, so that the methyl flavonoid compound can be used for treating acute lung injury. The traditional Chinese medicine composition disclosed by the invention can be used for reducing the generation of lung effusion, reducing the wet weight of the lung and inhibiting the rising degree of the ratio of wet weight to dry weight of the lung caused by acute lung injury, so that the effects of resisting inflammation and inhibiting lung edema are achieved, the acute inflammatory injury of the lung can be effectively reduced, respiratory distress is delayed or weakened, and the symptoms of severe and critical patients are relieved; the medicine can be used for preventing or treating acute lung injury.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of a methyl flavonoid compound in the preparation of drugs for preventing or treating acute lung injury and / or acute respiratory distress syndrome. Background technique [0002] Acute lung injury (ALI) / acute respiratory distress syndrome (ARDS) is caused by various direct (various types of pneumonia, foreign body aspiration, etc.) and indirect injury factors (trauma, infection, shock, etc.) Cell and capillary endothelial cell damage, resulting in diffuse pulmonary interstitial and alveolar edema, resulting in acute hypoxic respiratory insufficiency. ALI and ARDS have the same pathophysiological changes, and severe ALI or the final severe stage of ALI is defined as ARDS. [0003] The pathogenesis of ALI / ARDS is very complicated, because the body is often attacked by endogenous or exogenous pathogenic microorganisms and their metabolites, and poisoning, shock, acu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61K31/353A61K31/35A61K31/37A61K31/7034A61K31/7048A61P9/10A61P11/00A61P31/04A61P31/12A61P31/14A61P31/22A61P7/08
CPCA61K31/352A61K31/353A61K31/35A61K31/37A61K31/7034A61K31/7048A61P9/10A61P11/00A61P31/04A61P31/12A61P31/14A61P31/22A61P7/08
Inventor 温尧林徐海霞许容颜
Owner CATCH BIO SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com